Biotechnology & Life Sciences M&A Transactions

Clarenta Group strengthens early-stage drug development with the acquisition of Leads To Development, integrating preclinical and regulatory expertise.

Webster Equity Partners to acquire Lifecore Biomedical in a deal valued up to $663.7M, enhancing its position in sterile injectable pharmaceutical manufacturing.

AVS Bio, a portfolio company of Arlington Capital Partners, has acquired Biorbyt Ltd., enhancing its biomaterials offerings and global reach in life sciences research.

Novotech strengthens its bioanalytical capabilities in Australia by acquiring Agilex Biolabs from Healius, enhancing services for the life sciences sector.